Published Date: 02 Mar 2023
Researchers from the Barts Cancer Institute and the Francis Crick Institute at Queen Mary University of London have discovered why patients with rare blood cancers suffer from the development of poor red blood cells and...
Read Full NewsResearch reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.
The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.
Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.
Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.
IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis
1.
Spouses of Cancer Patients May Be at Increased Risk of Suicide
2.
How breast tissue density affects your risk of breast cancer
3.
Housing aid linked to lower medical financial hardship among US renters with cancer
4.
The Higher the Disability Burden From Disease, the Higher the Suicide Risk
5.
ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer
1.
The Rise of Immunotherapy: New Advances in Cancer Treatment
2.
Beyond the Tumor: Emerging Frontiers in Cancer Systems Biology
3.
Real-World Evidence and Patient Voices: Redefining Outcomes in Modern Oncology
4.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
5.
Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
Navigating the Complexities of Ph Negative ALL - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation